Member Info for MadEnglish

Dvh...it will be back and then some. Trust the science and the need for it.

ATB

ME

It matters not that people are selling, the science hasn't changed, the potential hasn't changed, the need for this science hasn't changed. When this moves it will move quickly and massively. Happy to sit on my holding.

ATB

ME

News tomorrow Fredd1e ?

Lets hope so eh !

ATB, ME

Based on recent industry activity, the most likely acquirer among top-tier pharmaceutical companies for Solvonis Therapeutics is AbbVie, as they have already shown active interest in acquiring similar addiction treatment pipelines.

Top Potential Acquirers

AbbVie: In 2025, reports indicated AbbVie was preparing a $1bn offer for Gilgamesh Pharmaceuticals, a U.S. peer in the same space, highlighting a strong strategic desire to enter this market.

Other Potential Top-10 Contenders: Given the high unmet need in CNS (Central Nervous System) disorders, other top-10 firms with strong histories of psychiatric or neurological acquisitions—such as Pfizer, Novartis, or Johnson & Johnson—are considered likely acquirers for de-risked late-stage assets.

Why Solvonis is an Attractive Target

Solvonis has positioned itself as a major player in addiction treatment, particularly following its acquisition of Awakn Life Sciences in May 2025.

Lead Asset (SVN-001): A Phase 3, first-of-its-kind combination therapy (IV ketamine + manualized CBT) for severe Alcohol Use Disorder (AUD), with results expected in late 2027/early 2028.

US Market Asset (SVN-002):

A sublingual/buccal esketamine formulation for moderate-to-severe AUD, which may follow a "regulatory shortcut" to bypass early trials, reducing cost and time-to-market.

Discovery Engine:

A pipeline targeting stimulant addiction (methamphetamine/cocaine) and a PTSD program (SVN-SDN-14).

Timing and Strategic Drivers

Late-Stage Focus:

Solvonis explicitly positioned itself as a "partner of choice" for large pharma, with discussions already underway for licensing SVN-001.

High Value Target:

With positive Phase 2b data, the assets are considered de-risked, and similar deals in this space have commanded up to $1.2 billion in total value.

We don't get traders off-loading the second we head back into the 3s.

ATB

NF...timed to allow folks to exit

And yet here you are.

Well said Bod, this will definitely be massive, 2p will be easily achieved, when Unilever and AstraZeneca come fully into play there will be many PIs kicking themselves for taking their .5p profits.

ATB

ME

LHogbog, just keep holding, this is going to blow the bl00dy doors off one day. When this gets picked up, JVd, bought out, it'll be by a big player and you'll be so happy you were in @ .3p.

ATB

ME

Hi MrWilks,

Likewise. I go back to BlueJay, I was going to write a similar post earlier but with all the noise, I thought Why Bother, while I don't like negativity you also have to be realistic, both camps are working equally hard to out gun the other, today for all the ' definitely a blue finish ' hype , it didn't. When the US market opens, this'll fly, it didn't.

Hopefully it will yet but nothing posted on here will cause the movement either way.

New investors DYOR and don't just get caught up in the Greenland hype.

ATB

ME

Next week Rodney...😁

ATB

Yes, sir, sitting here thinking next week could be a wonderful finish to January and the start of much upward trajectory for us . Nice to see the Blue finish.

ATB

ME

VR...hold on 80M is up around 10% and yet you're up over 100 % 🤔

Good luck VR.

Https://thatstocksguy.substack.com/p/solvonis-therapeutics

Well said Fredd1e, patience and adding as I can while its under 1p.

ATB

ME

No not mad, just a little humour aimed at you wanting the SP that low.

ATB

Takayama, no offence intended but here's a little word puzzle for you...FufcOfk 😁

Sorry Dusty, not today.

ATB

ME